Related Experiment Videos
Glucocorticosteroids for viral hepatitis C
J Brok1, M T Mellerup, K Krogsgaard
1Centre for Clinical Intervention Research, Copenhagen University Hospital, Department 7102, H:S Rigshospitalet, Copenhagen Ø, Denmark, DK 2100.
The Cochrane Database of Systematic Reviews
|April 24, 2004
Summary
Glucocorticosteroids show no significant benefit or harm for chronic hepatitis C patients. More research is needed to confirm effects and rule out serious adverse events in hepatitis C virus patients.
Area of Science:
- Hepatology
- Clinical Pharmacology
Background:
- Hepatitis C virus (HCV) infection can lead to liver inflammation and fibrosis.
- The role of glucocorticosteroids in managing HCV infection remains unclear.
Purpose of the Study:
- To assess the efficacy and safety of glucocorticosteroids in patients with acute or chronic hepatitis C.
- To evaluate outcomes in patients with or without HCV-related autoimmune disorders.
Main Methods:
- Systematic review of randomized clinical trials.
- Searches conducted across multiple databases (Cochrane Hepato-Biliary, CENTRAL, MEDLINE, EMBASE) up to July 2003.
- Data extraction and validation by two independent reviewers.
Main Results:
- Eight trials involving 384 patients with chronic hepatitis C were analyzed.
- Glucocorticosteroids combined with interferon showed no significant impact on mortality, virological, or biochemical response compared to interferon monotherapy.
- No trials investigated glucocorticosteroids for acute hepatitis C.
Conclusions:
- Insufficient evidence exists to confirm or refute the benefits or harms of glucocorticosteroids in chronic hepatitis C.
- Potential serious adverse effects of glucocorticosteroids cannot be excluded.
- The safety of glucocorticosteroids in patients with underlying HCV infection requires further investigation.